INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 279 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,641,000 | +94.9% | 83,556 | +151.6% | 0.00% | – |
| Q2 2023 | $1,355,000 | +30.4% | 33,212 | +19.2% | 0.00% | – |
| Q1 2023 | $1,039,000 | -17.8% | 27,866 | -23.1% | 0.00% | – |
| Q4 2022 | $1,264,000 | +18.5% | 36,222 | +89.9% | 0.00% | – |
| Q3 2022 | $1,067,000 | +1.7% | 19,072 | -5.9% | 0.00% | – |
| Q2 2022 | $1,049,000 | -53.0% | 20,276 | -34.0% | 0.00% | -100.0% |
| Q1 2022 | $2,232,000 | -40.9% | 30,707 | -3.8% | 0.00% | 0.0% |
| Q4 2021 | $3,775,000 | +18.6% | 31,913 | +34.4% | 0.00% | 0.0% |
| Q3 2021 | $3,184,000 | -12.8% | 23,741 | +5.2% | 0.00% | 0.0% |
| Q2 2021 | $3,653,000 | +89.2% | 22,563 | -6.3% | 0.00% | 0.0% |
| Q1 2021 | $1,931,000 | -71.9% | 24,068 | -80.9% | 0.00% | -50.0% |
| Q4 2020 | $6,864,000 | +175.1% | 126,180 | +0.5% | 0.00% | +100.0% |
| Q3 2020 | $2,495,000 | -7.0% | 125,497 | -1.7% | 0.00% | 0.0% |
| Q2 2020 | $2,683,000 | +84.4% | 127,618 | +7.2% | 0.00% | 0.0% |
| Q1 2020 | $1,455,000 | -19.9% | 119,038 | -3.9% | 0.00% | 0.0% |
| Q4 2019 | $1,817,000 | +3.2% | 123,853 | -6.1% | 0.00% | 0.0% |
| Q3 2019 | $1,760,000 | -19.6% | 131,845 | -1.4% | 0.00% | 0.0% |
| Q2 2019 | $2,189,000 | +262.4% | 133,723 | +277.9% | 0.00% | – |
| Q1 2019 | $604,000 | +36.7% | 35,384 | +9.1% | 0.00% | – |
| Q4 2018 | $442,000 | -59.9% | 32,434 | -15.7% | 0.00% | – |
| Q3 2018 | $1,101,000 | +3.9% | 38,465 | -0.7% | 0.00% | – |
| Q2 2018 | $1,060,000 | +65.6% | 38,740 | +27.8% | 0.00% | – |
| Q1 2018 | $640,000 | +588.2% | 30,320 | +521.7% | 0.00% | – |
| Q4 2017 | $93,000 | -41.5% | 4,877 | -23.8% | 0.00% | – |
| Q3 2017 | $159,000 | +74.7% | 6,403 | +13.1% | 0.00% | – |
| Q2 2017 | $91,000 | +49.2% | 5,659 | +31.5% | 0.00% | – |
| Q1 2017 | $61,000 | -47.9% | 4,302 | -51.7% | 0.00% | – |
| Q4 2016 | $117,000 | -14.0% | 8,915 | +11.0% | 0.00% | – |
| Q3 2016 | $136,000 | – | 8,034 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |